Verificador de elegibilidad GLP-1
Estima para qué medicamentos GLP-1 probablemente cumples los requisitos según las indicaciones de la FDA, en función del IMC, la edad y las comorbilidades. Solo informativo — la decisión final corresponde a tu médico.
What This Checker Estimates
The GLP-1 Eligibility Checker compares your BMI, age, and comorbidities against current FDA labeling for Wegovy, Zepbound, Saxenda, Ozempic, and Mounjaro. Wegovy and Zepbound require BMI ≥30, or ≥27 with at least one weight-related condition. Zepbound was expanded in 2024 to treat moderate-to-severe obstructive sleep apnea in adults with obesity. Ozempic and Mounjaro carry an FDA-labeled indication only for type 2 diabetes — though the molecules (semaglutide, tirzepatide) are the same as Wegovy and Zepbound for weight management.
Who Is This For?
Anyone trying to understand whether they are likely to qualify for a GLP-1 prescription before talking to a prescriber. The result is informational — your real eligibility depends on your full medical history, insurance plan rules, and your prescriber's clinical judgment.
Preguntas frecuentes
What BMI qualifies for Wegovy or Zepbound?
FDA labeling requires BMI ≥30, OR BMI ≥27 with at least one weight-related condition (e.g., type 2 diabetes, hypertension, high cholesterol, OSA).
Can I get Ozempic or Mounjaro just for weight loss?
Ozempic and Mounjaro are FDA-approved for type 2 diabetes only. Their semaglutide/tirzepatide molecules are also sold as Wegovy and Zepbound for weight management. Off-label prescribing exists but coverage and access vary widely.
Does sleep apnea make me eligible for Zepbound?
Yes. In late 2024 the FDA expanded Zepbound to treat moderate-to-severe obstructive sleep apnea in adults with obesity (BMI ≥30).
What if my BMI is just under 30?
BMI 27–29.9 plus at least one weight-related condition meets FDA labeling for Wegovy and Zepbound. Without a comorbidity, you generally do not meet labeled criteria.
Does insurance follow FDA labeling?
Not always. Many commercial plans require additional documentation (prior authorization, lifestyle attempts) or restrict GLP-1s to type 2 diabetes. Medicare does not cover GLP-1s for weight loss as of 2026.
Lecturas relacionadas
Guarda tu resultado
Envíate una copia por correo y únete al boletín semanal de Gila — investigación práctica sobre GLP-1, sin spam.
Estas herramientas son solo informativas y no constituyen consejo médico. Siempre consulta a tu profesional de la salud.
¿Listo/a para comenzar tu camino con GLP-1?
Gila te ayuda a construir hábitos duraderos, entender tu cuerpo y mantener el rumbo. Únete al piloto gratis.
Únete al piloto